Compare DQ & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DQ | MESO |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 2010 | N/A |
| Metric | DQ | MESO |
|---|---|---|
| Price | $32.00 | $17.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $32.50 | $24.00 |
| AVG Volume (30 Days) | ★ 911.9K | 211.8K |
| Earning Date | 10-27-2025 | 08-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $639,063,000.00 | $17,198,000.00 |
| Revenue This Year | N/A | $465.44 |
| Revenue Next Year | $58.56 | $75.37 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 191.39 |
| 52 Week Low | $12.41 | $9.61 |
| 52 Week High | $36.59 | $22.00 |
| Indicator | DQ | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 50.75 | 56.73 |
| Support Level | $31.72 | $16.43 |
| Resistance Level | $34.50 | $17.65 |
| Average True Range (ATR) | 1.60 | 0.59 |
| MACD | -0.04 | 0.16 |
| Stochastic Oscillator | 47.40 | 56.31 |
Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.